Skip to main content
SpringerLink
Log in

18F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Objectives

The objectives of this study were to reveal the utility of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) within 7 days after chemoradiotherapy to predict prognosis in patients with postoperative recurrent esophageal cancer.

Materials and methods

Patients scheduled to undergo concurrent chemoradiotherapy for postoperative locoregional recurrence of esophageal cancer were recruited. Selection criteria were: (1) locoregional recurrence, (2) no previous radiation therapy, (3) planning treatment with concurrent chemoradiotherapy, (4) FDG-PET performed <2 weeks before chemoradiotherapy, and (5) no serious diabetes. FDG-PET was performed <7 days after chemoradiotherapy. No more treatment after chemoradiotherapy was given until disease progression was diagnosed according to the Response Evaluation Criteria in Solid Tumors (RECIST). Correlations of FDG-PET findings with cause-specific survival and local control rates were investigated prospectively.

Results

Twenty patients were enrolled. Median observation period of patients who survived was 45.0 months. Median maximum standardized uptake value (SUVmax) after chemoradiotherapy was 2.4, and median SUVmax before chemoradiotherapy was 8.4. Cause-specific survival and local control rates were significantly better for patients with SUVmax ≤ 2.4 after chemoradiotherapy (log-rank test, P = 0.033 and 0.010, respectively). SUVmax before chemoradiotherapy tended to be correlated only with cause-specific survival rate (log-rank test, P = 0.076). Change in metabolic activity of FDG was significantly correlated with local control rate (log-rank test, P = 0.042).

Conclusions

FDG-PET performed even <7 days after chemoradiotherapy predicts prognosis in patients with postoperative recurrent esophageal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Flamen P, Lerut A, Van Cutsem E et al (2000) The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 120:1085–1092

    Article  CAS  PubMed  Google Scholar 

  2. Kato H, Miyazaki T, Nakajima M et al (2004) Value of positron emission tomography in the diagnosis of recurrent oesohageal carcinoma. Br J Surg 91:1004–1009

    Article  CAS  PubMed  Google Scholar 

  3. Duong CP, Demitriou H, Weih L et al (2006) Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging 33:759–769

    Article  PubMed  Google Scholar 

  4. Kato H, Kuwano H, Nakajima M et al (2002) Comparison between positron emission tomography and computed tomography in the use of assessment of esophageal carcinoma. Cancer 94:921–928

    Article  PubMed  Google Scholar 

  5. Fukunaga T, Okazumi S, Koide Y et al (1998) Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 39:1002–1007

    CAS  PubMed  Google Scholar 

  6. Blackstock AW, Farmer MR, Lovato J et al (2006) A prospective evaluation of the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 64:455–460

    PubMed  Google Scholar 

  7. Swisher SG, Erasmus J, Maish M et al (2004) 2-Fluoro-2-deoxy-d-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 15:1776–1785

    Article  Google Scholar 

  8. Downey RJ, Akhurst T, Ilson D et al (2003) Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21:428–432

    Article  PubMed  Google Scholar 

  9. Brucher BL, Weber W, Bauer M et al (2001) Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233:300–309

    Article  CAS  PubMed  Google Scholar 

  10. Nishimura Y, Koike R, Nakamatsu K et al (2003) Concurrent chemoradiotherapy with protracted infusion of 5-FU and Cisplatin for postoperative recurrent or residual esophageal cancer. Jpn J Clin Oncol 33:341–345

    Article  PubMed  Google Scholar 

  11. Raoul JL, Le Prise E, Meunier B et al (1995) Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut 37:174–176

    Article  CAS  PubMed  Google Scholar 

  12. Shimada H, Kitabayashi H, Nabeya Y et al (2003) Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 133:24–31

    Article  PubMed  Google Scholar 

  13. Nemoto K, Ariga H, Kakuto Y et al (2001) Radiation therapy for loco-regionally recurrent esophageal cancer after surgery. Radiother Oncol 61:165–168

    Article  CAS  PubMed  Google Scholar 

  14. Nemoto K, Matsushita H, Ogawa Y et al (2003) Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. Am J Clin Oncol 26:46–49

    Article  CAS  PubMed  Google Scholar 

  15. Yamanaka H, Motohiro T, Michiura T et al (1998) Nedaplatin and 5-FU combined with radiation in treatment for esophageal cancer. Jpn J Thorac Cardiovasc Surg 10:943–948

    Google Scholar 

  16. Jingu K, Nemoto K, Matsushita H et al (2006) Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-Fluorouracil for postoperative locoregional recurrent esophageal cancer. BMC Cancer 6:50

    Article  PubMed  Google Scholar 

  17. Kubota R, Yamada S, Kubota K et al (1992) Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33:1972–1980

    CAS  PubMed  Google Scholar 

  18. Kubota K, Yokoyama J, Yamaguchi K et al (2004) FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging 31:590–595

    Article  PubMed  Google Scholar 

  19. Kato H, Kuwano H, Nakajima M et al (2002) Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 184:279–283

    Article  PubMed  Google Scholar 

  20. Schmidt M, Bollschweiler E, Dietlein M et al (2009) Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging 36:735–744

    Article  CAS  PubMed  Google Scholar 

  21. Lodge MA, Lucas JD, Marsden PK et al (1999) A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 26:22–30

    Article  CAS  PubMed  Google Scholar 

  22. Nakamoto Y, Higashi T, Sakahara H et al (2000) Delayed (18)F-fluoro-2-deoxy-d-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 89:2547–2554

    Article  CAS  PubMed  Google Scholar 

  23. Zhuang H, Pourdehnad M, Lambright ES et al (2001) Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42:1412–1417

    CAS  PubMed  Google Scholar 

  24. Matthies A, Hickeson M, Cuchiara A et al (2002) Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43:871–875

    PubMed  Google Scholar 

  25. Ma SY, See LC, Lai CH C et al (2003) Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 44:1775–1783

    PubMed  Google Scholar 

  26. Yen TC, Chang YC, Chan SC et al (2005) Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes? Eur J Nucl Med Mol Imaging 32:541–548

    Article  PubMed  Google Scholar 

  27. Flamen P, Van Cutsem E, Lerut A et al (2002) Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13:361–368

    Article  CAS  PubMed  Google Scholar 

  28. Kostakoglu L, Goldsmith SJ (2004) PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 45:56–68

    PubMed  Google Scholar 

  29. Weber WA, Ott K, Becker K et al (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058–3065

    CAS  PubMed  Google Scholar 

  30. Wieder HA, Brucher BL, Zimmermann F et al (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22:900–908

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest statement

There is no conflict of interest in relation to this study.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan

    Keiichi Jingu, Ken Takeda, Yoshihiro Ogawa, Hisanori Ariga, Masashi Koto, Toru Sakayauchi, Yoshihiro Takai & Shogo Yamada

  2. Department of Diagnostic Radiology, Tohoku University School of Medicine, Sendai, Japan

    Tomohiro Kaneta & Shoki Takahashi

  3. Department of Radiation Oncology, Yamagata University School of Medicine, Yamagata, Japan

    Kenji Nemoto

Authors
  1. Keiichi Jingu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomohiro Kaneta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenji Nemoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ken Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshihiro Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hisanori Ariga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masashi Koto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toru Sakayauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshihiro Takai
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shoki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shogo Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keiichi Jingu.

About this article

Cite this article

Jingu, K., Kaneta, T., Nemoto, K. et al. 18F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer. Int J Clin Oncol 15, 184–190 (2010). https://doi.org/10.1007/s10147-010-0044-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-010-0044-y

Keywords

Search

Navigation